

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 February 2017 (23.02.2017)



(10) International Publication Number
WO 2017/031104 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2016/047146

(22) International Filing Date:
16 August 2016 (16.08.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/206,246 17 August 2015 (17.08.2015) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV**
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant (for US only): **PILLARISETTI, Kodandaram**
[US/US]; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US).

(72) Inventors: **BALDWIN, Eric Thomas**; 1400 McKean
Road, Spring House, Pennsylvania 19477 (US).
POWERS, Gordon D.; 1400 McKean Road, Spring
House, Pennsylvania 19477 (US). **CARDOSO, Rosa
Maria Fernandes**; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US). **ATTAR, Ricardo**; 1400 McK-
ean Road, Spring House, Pennsylvania 19477 (US).
GAUDET, Francois; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US).

(74) Agents: **DEBERARDINE, Robert** et al.; Johnson & John-
son, One Johnson & Johnson Plaza, New Brunswick, New
Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES THEREOF

(57) Abstract: Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD 3 described herein.



WO 2017/031104 A1